Another major drawback is the fact that the majority of the already established HDAC inhibitors are only approved for the treatment of T-cell lymphomas, due to insufficient efficacy against solid tumors (Slingerland et al., 2014). This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.